Polymer Capital Management HK LTD Boosts Position in Summit Therapeutics PLC $SMMT

Posted by Stanley Muller on Jun 13th, 2026

Polymer Capital Management HK LTD boosted its position in Summit Therapeutics PLC (NASDAQ:SMMT – Free Report) by 73.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,421,155 shares of the company’s stock after buying an additional 603,879 shares during the quarter. Summit Therapeutics comprises 3.5% of Polymer Capital Management HK LTD’s investment portfolio, making the stock its 7th largest holding. Polymer Capital Management HK LTD’s holdings in Summit Therapeutics were worth $24,856,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Tudor Investment Corp ET AL bought a new position in Summit Therapeutics in the third quarter valued at about $7,174,000. Vanguard Group Inc. boosted its holdings in Summit Therapeutics by 31.2% in the third quarter. Vanguard Group Inc. now owns 11,379,728 shares of the company’s stock valued at $235,105,000 after acquiring an additional 2,706,056 shares during the last quarter. WINTON GROUP Ltd bought a new position in Summit Therapeutics in the third quarter valued at about $1,341,000. Assenagon Asset Management S.A. bought a new position in Summit Therapeutics in the fourth quarter valued at about $1,043,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its holdings in Summit Therapeutics by 409.2% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 338,363 shares of the company’s stock valued at $6,991,000 after acquiring an additional 271,912 shares during the last quarter. Institutional investors own 4.61% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on SMMT. Stifel Nicolaus began coverage on Summit Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $45.00 price target on the stock. Zacks Research upgraded Summit Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th. Truist Financial upgraded Summit Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Piper Sandler decreased their price target on Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a report on Friday, May 1st. Finally, Jefferies Financial Group cut Summit Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $42.00 to $15.00 in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Summit Therapeutics currently has an average rating of “Hold” and a consensus price target of $27.23.

Check Out Our Latest Research Report on Summit Therapeutics

Summit Therapeutics Trading Up 7.1%

Shares of SMMT opened at $14.01 on Friday. Summit Therapeutics PLC has a 1 year low of $12.55 and a 1 year high of $30.98. The stock has a market cap of $10.87 billion, a P/E ratio of -8.76 and a beta of -1.32. The stock’s 50-day moving average price is $18.55 and its two-hundred day moving average price is $17.35.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last issued its earnings results on Friday, May 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. As a group, equities analysts forecast that Summit Therapeutics PLC will post -1.18 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Robert W. Duggan bought 3,810,000 shares of Summit Therapeutics stock in a transaction on Friday, June 12th. The shares were purchased at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the acquisition, the chief executive officer owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mahkam Zanganeh bought 3,810,000 shares of Summit Therapeutics stock in a transaction on Friday, June 12th. The shares were bought at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the acquisition, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. The trade was a 0.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 7,870,000 shares of company stock worth $103,616,900. Insiders own 83.50% of the company’s stock.

Summit Therapeutics Profile

(Free Report)

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.